200 related articles for article (PubMed ID: 23028980)
1. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
Keppeke GD; Nunes E; Ferraz ML; Silva EA; Granato C; Chan EK; Andrade LE
PLoS One; 2012; 7(9):e45392. PubMed ID: 23028980
[TBL] [Abstract][Full Text] [Related]
2. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Stinton LM; Myers RP; Coffin CS; Fritzler MJ
BMC Gastroenterol; 2013 Mar; 13():50. PubMed ID: 23506439
[TBL] [Abstract][Full Text] [Related]
3. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
6. Association of Autoantibody to Rods and Rings with Hepatitis C Outcome and Viral Load.
Dhaouadi T; Abdellatif J; Jallouli M; Mejdoubi M; Sfar I; Mouelhi L; Aouini S; Ben Abdallah T; Gorgi Y
Viral Immunol; 2019 Jun; 32(5):214-220. PubMed ID: 31081724
[TBL] [Abstract][Full Text] [Related]
7. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Keppeke GD; Satoh M; Ferraz ML; Chan EK; Andrade LE
Immunol Res; 2014 Oct; 60(1):38-49. PubMed ID: 24845459
[TBL] [Abstract][Full Text] [Related]
8. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.
Carcamo WC; Ceribelli A; Calise SJ; Krueger C; Liu C; Daves M; Villalta D; Bizzaro N; Satoh M; Chan EK
J Clin Immunol; 2013 Feb; 33(2):420-6. PubMed ID: 23100146
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2018 Oct; 66(5):605-610. PubMed ID: 30220012
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
[TBL] [Abstract][Full Text] [Related]
11. Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2020 Jun; 68(3):111-117. PubMed ID: 32537670
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
14. Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.
Novembrino C; Aghemo A; Ferraris Fusarini C; Maiavacca R; Matinato C; Lunghi G; Torresani E; Ronchi M; Garlaschi MC; Ramondetta M; Colombo M
J Viral Hepat; 2014 Dec; 21(12):944-9. PubMed ID: 25040504
[TBL] [Abstract][Full Text] [Related]
15. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies.
Keppeke GD; Prado MS; Nunes E; Perazzio SF; Rodrigues SH; Ferraz ML; Chan EK; Andrade LE
Clin Immunol; 2016 Dec; 173():149-156. PubMed ID: 27746381
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
17. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
19. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
[TBL] [Abstract][Full Text] [Related]
20. High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.
Wartelle-Bladou C; Arpurt JP; Renou C; Pariente A; Pillon D; Nalet B; Picon M; Glibert A; Chousterman M; Grasset D; Morin T; Bernard P; Fischer D; Ramdani M; Lagier E; Rotily M;
Gastroenterol Clin Biol; 2006 Apr; 30(4):525-32. PubMed ID: 16733374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
